Latest Ratios: P/E Ratio -20.7x · EV/EBITDA N/A · ROE -22.7%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.2B | $964M | $1.2B | $1.2B | $1.4B | $1.0B | — | — |
| Enterprise Value | $2.0B | $769M | $1.1B | $934M | $1.3B | $760M | — | — |
| P/E Ratio → | -20.70 | — | — | — | — | — | — | — |
| P/S Ratio | 14.06 | 6.09 | 9.04 | — | — | — | — | — |
| P/B Ratio | 5.05 | 2.18 | 2.36 | 3.36 | 4.24 | 3.71 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.86 | 8.11 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.1% | 89.1% | 96.0% | — | — | — | — | — |
| Operating Margin | -80.8% | -80.8% | -165.7% | — | — | — | — | — |
| Net Profit Margin | -67.8% | -67.8% | -72.8% | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -22.7% | -22.7% | -22.5% | -55.7% | -46.4% | -43.5% | -211.7% | — |
| ROA | -19.7% | -19.7% | -19.9% | -52.1% | -44.5% | -42.1% | -111.0% | -46.2% |
| ROIC | -30.5% | -30.5% | -65.6% | -85.0% | -90.1% | — | — | — |
| ROCE | -26.7% | -26.7% | -50.8% | -60.7% | -47.9% | -44.8% | -40.0% | -58.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.44 | -0.24 | -0.66 | -0.25 | -1.01 | -1.00 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -1460.43 | -7.18 |
Net cash position: cash ($197M) exceeds total debt ($3M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.02 | 8.02 | 7.66 | 12.72 | 20.94 | 33.43 | 22.58 | 13.53 |
| Quick Ratio | 7.91 | 7.91 | 7.61 | 12.72 | 20.94 | 33.43 | 22.58 | 13.53 |
| Cash Ratio | 7.29 | 7.29 | 7.24 | 12.42 | 20.60 | 32.84 | 21.91 | 13.52 |
| Asset Turnover | — | 0.31 | 0.23 | — | — | — | — | — |
| Inventory Turnover | 2.72 | 2.72 | 1.59 | — | — | — | — | — |
| Days Sales Outstanding | — | 61.69 | 38.61 | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $103M | $94M | $80M | $65M | $62M | $62M | $62M |
Single asset commercial dependency
Based on reported figures, DAWN trades at a P/S multiple of 14.06, which suggests that the market is pricing in significant future growth from the Ojemda commercial rollout rather than current earnings, which remain negative as the company scales its specialized pediatric oncology sales force.
The current valuation appears to be heavily contingent on the successful penetration of the front-line pLGG market, as the forward EV/EBITDA of 25.24 implies an expectation of rapid margin expansion. Investors should monitor whether this premium holds if the FIREFLY-2 trial results deviate from the high expectations currently embedded in the stock price.
According to recent financial statements, DAWN's ROIC has remained consistently negative, bottoming at -6.3% in 2025Q4, which reflects the substantial capital intensity required to support clinical development and the early-stage commercialization of its lead asset in a niche pediatric oncology market.
The negative return profile is a structural reality of the company's current development phase, where the cost of capital is deployed into long-term R&D rather than immediate yield-generating assets. Until the company achieves a sustainable scale in Ojemda prescriptions, ROIC will likely remain a secondary metric compared to the clinical trial progress.
As reported in quarterly filings, DAWN's cash conversion cycle has fluctuated significantly, reaching 67 days in 2025Q4, which highlights the operational challenges of managing inventory and accounts receivable during the initial commercial launch phase of a specialized orphan drug product.
The variability in the CCC suggests that the company is still refining its supply chain and distribution logistics for Ojemda. Investors should monitor the DSO and DIO trends to ensure that the transition to commercial-stage operations does not lead to inefficient capital tie-ups in inventory or delayed collections from institutional payers.
Based on the provided data, DAWN maintains a current ratio of 8.02 as of 2025Q4, providing a substantial liquidity cushion that appears sufficient to fund the company's ongoing commercial rollout and clinical trial commitments despite the persistent quarterly cash burn observed in recent periods.
This strong liquidity position is largely a result of disciplined capital management, including the non-dilutive monetization of the Priority Review Voucher. This buffer provides management with the necessary runway to execute on the FIREFLY-2 trial without the immediate pressure of seeking dilutive equity financing in a volatile market.
The P/E ratio is the most commonly misapplied metric for DAWN, as it obscures the company's true economic potential by focusing on GAAP net losses that are heavily influenced by non-recurring R&D investments and stock-based compensation rather than sustainable commercial performance.
Investors should instead focus on metrics like EV/Sales or patient-start growth, which better capture the underlying commercial trajectory of Ojemda. Relying on P/E in this context may lead to an incorrect assessment of the company's value, as it fails to account for the significant optionality inherent in the pipeline.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying DAWN stock.
Day One Biopharmaceuticals, Inc.'s current P/E ratio is -20.7x. This places it at the 50th percentile of its historical range.
Day One Biopharmaceuticals, Inc.'s return on equity (ROE) is -22.7%. The historical average is -67.1%.
Based on historical data, Day One Biopharmaceuticals, Inc. is trading at a P/E of -20.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Day One Biopharmaceuticals, Inc. has 89.1% gross margin and -80.8% operating margin.